ABRYSVO can help prevent lung disease caused
by RSV.
NOW YOU KNOW.
RSV in adults
For many adults, RSV infection is mild, causing cold-like symptoms that last 1–2 weeks. However, RSV can cause severe illness in adults with certain underlying risk factors and those over age 60.
Nearly
1 IN 5
ABRYSVO can help protect you from lower respiratory tract disease caused by RSV
ABRYSVO is a vaccine developed by Pfizer that can help prevent disease of the lower respiratory tract (lungs) caused by RSV (respiratory syncytial virus).
ABRYSVO is given to individuals 60 years of age and older and individuals 18–59 years of age who are at increased risk for lung disease caused by RSV.
As with any vaccine, ABRYSVO will not protect 100% of those who receive it. ABRYSVO is not a treatment for RSV infection or its complications.
ABRYSVO was given to
18,050
older adults during the Phase 3 trial
ABRYSVO was given to
453
adults aged 18 through 59 years at increased risk of severe RSV disease during its Phase 3 trial
The most common side effects reported were fatigue, headache, muscle pain, and pain where the injection was given.
Like all vaccines, ABRYSVO can cause side effects, although not everyone experiences them.
More questions? We have answers.
ICU=intensive care unit
ABRYSVO is a vaccine to help prevent disease of the lower respiratory tract (lungs) caused by RSV (respiratory syncytial virus). ABRYSVO is given to pregnant individuals (from 32 through 36 weeks’ gestation) to protect their infants from birth through 6 months of age, individuals 60 years of age and older, individuals 18-59 years of age who are at increased risk for lung disease caused by RSV. As with any vaccine, ABRYSVO will not protect 100% of those who receive it. ABRYSVO is not a treatment for RSV infection or its complications. Like all vaccines, ABRYSVO can cause side effects, although not everybody gets them.
For more information, please consult the Product Monograph or call 1-800-463-6001.